Kozak & Associates’s Idexx Laboratories IDXX Stock Holding History

Kozak & Associates’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-800	Closed	-$400K	–	360
2023 Q1	$400K	Hold	800	–	–	0.18%	57
2022 Q4	$326K	Hold	800	–	–	0.16%	58
2022 Q3	$261K	Hold	800	–	–	0.16%	65
2022 Q2	$281K	Hold	800	–	–	0.19%	54
2022 Q1	$420K	Hold	800	–	–	0.27%	44
2021 Q4	$420K	Hold	800	–	–	0.27%	44
2021 Q3	$495K	Buy	+800	New	+$538K	0.29%	40
2020 Q4	$402K	Buy	+800	New	+$358K	0.31%	40

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Kozak & Associates's IDXX Position: Q2 2023 in Review

Kozak & Associates sold out of Idexx Laboratories (IDXX) in Q2 2023, closing a stake of 800 shares — an estimated $400K sold.

Kozak & Associates first reported a position in IDXX in Q4 2020 and held it in 8 quarters. The position peaked at $495K in Q3 2021. 1,068 funds tracked by Wall St. Rank hold IDXX as of Q2 2023.

Kozak & Associates reported no remaining Idexx Laboratories position as of Q2 2023 after selling out during the quarter.
Kozak & Associates sold 800 Idexx Laboratories shares in Q2 2023, an estimated $400K.
Kozak & Associates first reported a position in Idexx Laboratories in Q4 2020 and held it in 8 quarters.
Kozak & Associates's Idexx Laboratories position peaked at $495K in Q3 2021.
1,068 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2023.

Based on Kozak & Associates's 13F filing for Q2 2023, filed 5 Jul 2023.